Circulating Tumor DNA in Lung Cancer: Early Detection, Monitoring, and Key Challenges
A lung tumour can leave traces of itself in the bloodstream long before it is easy to study with a scan or biopsy. These traces are tiny fragments of genetic material, shed by cancer cells as they grow, die, and interact with the body. For lung cancer, where early diagnosis and timely treatment choices can change the course of care, that signal matters.
Circulating tumour DNA, often shortened to ctDNA, is part of the wider field of “liquid biopsy”. Instead of taking tissue from a lung mass through an invasive procedure, clinicians can sometimes learn about the cancer from a blood sample. The test does not replace every scan or tissue biopsy, but it is becoming an important tool for detecting cancer signals, tracking response to treatment, and spotting signs of relapse.
This article is for information only and is not medical advice. Decisions about lung cancer testing and treatment should always be made with a qualified cancer care team.
What ctDNA is and why it matters in lung cancer
DNA is the instruction code inside cells. As cells naturally break down, they release fragments of DNA into the bloodstream. Most of this is normal cell-free DNA. In someone with cancer, a small part may come from tumour cells. That tumour-derived fraction is ctDNA.
In lung cancer, ctDNA can carry many types of information, including:
Driver mutations that help a tumour grow, such as changes in `EGFR`, `ALK`, `ROS1`, `BRAF`, `MET`, `RET`, `NTRK`, or `KRAS`
Resistance mutations that appear after treatment pressure
Tumour burden signals, where the amount of ctDNA can rise or fall with disease activity
Methylation patterns, chemical tags on DNA that may help identify where a cancer signal is coming from
The attraction is clear. Lung tumours can be hard to biopsy, especially when they sit deep in the chest or when a patient is too unwell for an invasive procedure. Tissue samples can also miss genetic variation because one biopsy captures only one part of a tumour. A blood test may reflect DNA shed from several tumour sites at once.
That said, ctDNA is usually present in very small amounts, especially in early-stage lung cancer. The test must find a faint signal in a busy background of normal DNA. This is why ctDNA testing needs careful lab methods, strong quality control, and interpretation by specialists.
How ctDNA may support early detection
Early detection is one of the most promising uses of ctDNA, but also one of the most difficult.
Lung cancer often produces few symptoms in its early stages. By the time symptoms such as persistent cough, breathlessness, chest pain, or weight loss appear, the disease may already be advanced. Low-dose CT screening can reduce lung cancer deaths in people at higher risk, such as long-term smokers or former smokers, and it remains the main evidence-based screening tool in many health systems.
ctDNA could add another layer. A blood test that finds a cancer signal could, in theory, help identify people who need imaging sooner or help clarify whether a suspicious lung nodule is more likely to be malignant.
Research in this area has focused on several approaches:
Looking for specific mutations linked to lung cancer
Measuring abnormal DNA methylation patterns
Combining ctDNA with protein markers or clinical risk factors
Using machine learning to distinguish cancer signals from background noise
Some recent multi-cancer early detection studies have shown that blood-based DNA signals can detect several cancers, including lung cancer, and can often suggest the likely tissue of origin. These tests tend to perform better when more tumour DNA is present, which usually means later-stage disease. Sensitivity in stage I lung cancer remains lower, because small tumours may shed very little DNA.
That is the central tension in early detection. The test is most needed when the tumour is smallest, but that is when the signal is hardest to find.
ctDNA may be most useful as part of a combined pathway rather than as a standalone screen. For example, it could help decide which indeterminate nodules found on CT need closer follow-up, or it could complement imaging in people who are at high risk. Researchers are still working out where it adds the most value without creating too many false alarms.
How ctDNA helps monitor lung cancer over time
Monitoring is where ctDNA is already showing strong clinical value. Lung cancer care often involves repeated decisions: whether treatment is working, whether a tumour has developed resistance, and whether cancer has returned after surgery or radiotherapy.
A blood test can often be repeated more easily than a tissue biopsy. That makes ctDNA useful across several stages of care.
Choosing targeted treatment
Advanced non-small cell lung cancer is now commonly tested for genetic changes that guide treatment. If a tumour has an `EGFR` mutation, for example, a patient may benefit from an EGFR-targeted drug. Other alterations, such as `ALK` or `ROS1` rearrangements, can also point to specific therapies.
Tissue testing remains the standard when good tumour tissue is available. But plasma ctDNA testing can help when:
Tissue is unavailable or too small for full testing
A biopsy is risky or delayed
Disease has spread to several sites
A faster result could guide urgent treatment planning
In many care pathways, a positive ctDNA result for a recognised driver mutation can support treatment decisions. A negative result is more complicated. It may mean there is no mutation, but it may also mean the tumour is not shedding enough DNA into the blood. In that case, tissue testing may still be needed.
Detecting resistance
Cancer changes under treatment pressure. A targeted drug may work well for months or years, then the tumour finds another route to grow. ctDNA can sometimes reveal the resistance mechanism.
For example, after treatment with some EGFR inhibitors, blood testing may detect new resistance mutations or other genomic changes. This can help clinicians choose the next therapy, enrol a patient in a clinical trial, or avoid treatment that is unlikely to work.
This is one of the most practical benefits of ctDNA: it can turn disease progression from a vague finding on a scan into a more specific biological explanation.
Tracking treatment response
When treatment works, the amount of ctDNA in blood often falls. When disease grows, ctDNA may rise. In some studies, ctDNA changes have appeared before clear changes on imaging.
This does not mean scans are no longer needed. Imaging shows where disease is and whether tumours are shrinking, stable, or growing. ctDNA adds a molecular view. Together, they can give a more complete picture.
For patients receiving immunotherapy, ctDNA may be especially helpful. Scans can be difficult to interpret because immune responses can sometimes make tumours look temporarily larger or inflamed. A falling ctDNA level may support the idea that treatment is working, while rising ctDNA may raise concern about true progression.
Recent research shows real promise
The evidence base for ctDNA in lung cancer has grown quickly. Several themes keep appearing across recent studies.
One major area is minimal residual disease, often called MRD. After surgery for early-stage lung cancer, scans may show no visible disease. Yet a small number of cancer cells can remain and later cause relapse. ctDNA testing aims to detect that hidden disease.
Research from large lung cancer programmes, including studies linked to the TRACERx project in non-small cell lung cancer, has shown that ctDNA detection after surgery can be associated with a higher risk of relapse. Some findings suggest ctDNA may identify recurrence months before it appears on standard imaging. This creates a possible window for earlier intervention, though the best treatment response to an MRD-positive result is still being studied.
Another active area is matching advanced lung cancer patients to targeted therapy. Studies comparing plasma genotyping with tissue testing have shown that ctDNA can identify many clinically important mutations. Blood testing can also produce results quickly, which matters when disease is advanced and treatment should not be delayed.
Research has also explored ctDNA during immunotherapy. Several studies suggest that early clearance or marked reduction of ctDNA after treatment begins may be linked with better outcomes. By contrast, persistent or rising ctDNA may signal a higher chance of progression.
ctDNA is powerful because it can show how a tumour is changing in real time, but it is most useful when interpreted alongside scans, symptoms, pathology, and the patient’s overall health.
The direction of travel is clear. ctDNA is moving from a research tool into routine cancer care in selected settings, especially in advanced non-small cell lung cancer. For early detection and MRD-guided therapy, the science is promising, but practice is still evolving.
Benefits for treatment decisions and patient outcomes
The value of ctDNA is not just that it is technically impressive. Its real importance lies in what it may help clinicians do.
It can reduce delays. A blood test may be faster and safer than arranging another tissue biopsy, especially when a patient is frail or when the tumour is difficult to reach.
It can guide more precise treatment. Finding a driver mutation can open the door to a targeted therapy that may work better than non-specific treatment for that cancer type.
It can reveal resistance earlier. When a treatment stops working, ctDNA can sometimes identify why, which helps guide the next step.
It can support closer monitoring. Repeated blood tests may show molecular changes over time, giving clinicians another way to judge response.
It may help personalise follow-up after surgery. If MRD testing becomes more established, ctDNA could help identify which patients need additional treatment and which may be able to avoid unnecessary therapy.
These benefits connect directly to patient outcomes. Better treatment matching can improve response rates for some patients. Earlier detection of relapse may allow earlier care planning. Avoiding unnecessary invasive biopsies can reduce discomfort and risk.
Still, ctDNA is not a magic answer. A useful test must change care in a way that helps people live longer, live better, or avoid harm. That is why ongoing trials are so important. They are asking not only whether ctDNA can detect cancer signals, but whether acting on those signals improves outcomes.
Challenges and limitations that still need solving
ctDNA has clear promise, but several barriers limit its use.
Early-stage cancer can be hard to detect
Small lung cancers may shed little or no ctDNA. A negative blood test cannot safely rule out cancer, especially if imaging or symptoms raise concern. This is one reason ctDNA is not a replacement for low-dose CT screening or diagnostic scans.
False positives can happen
Not every mutation in blood comes from a tumour. As people age, blood-forming cells can acquire mutations, a process known as clonal haematopoiesis. These mutations can appear in cell-free DNA and may be mistaken for cancer-related changes if testing and interpretation are not careful.
This matters because a false positive result can lead to anxiety, extra scans, and invasive procedures.
Test methods vary
Different ctDNA tests use different technologies, gene panels, depth of sequencing, and reporting thresholds. Some look for a small number of known mutations. Others search across many genes or include methylation markers.
That variety can be useful, but it also makes results harder to compare. Health systems need clear standards for sample handling, test validation, reporting, and clinical use.
Access is uneven
ctDNA testing may not be available in every hospital or region. Cost, laboratory capacity, clinician familiarity, and reimbursement rules all shape access. Even where testing exists, turnaround time can vary.
This creates a fairness issue. A test that guides modern lung cancer care should not be available only to people treated in certain centres or able to pay privately.
Results need expert interpretation
A ctDNA report can be complex. It may include mutation names, allele fractions, uncertain variants, and comments about test sensitivity. Misreading the report can lead to poor decisions.
The best use of ctDNA usually involves a multidisciplinary team, including oncologists, pathologists, molecular scientists, radiologists, surgeons, specialist nurses, and genetic counsellors when inherited findings are relevant.
The future of ctDNA in lung cancer care
The next phase of ctDNA research is likely to focus on how to use results in real clinical decisions. Detecting a signal is only step one. The harder question is what to do next.
In early-stage lung cancer, trials are testing whether MRD-positive patients benefit from additional treatment after surgery, and whether MRD-negative patients can safely avoid some therapy. In advanced disease, research continues to refine how ctDNA can guide drug selection, detect resistance, and track response during targeted therapy and immunotherapy.
There is also growing interest in combining ctDNA with other information, such as imaging features, protein markers, clinical risk factors, and artificial intelligence tools. A single blood result may not tell the whole story. A combined model may give a clearer and safer estimate of risk.
For now, the most balanced view is this: ctDNA is already useful in selected parts of lung cancer care, and it may become much more important as evidence grows. It offers a less invasive way to study tumour biology, follow disease activity, and guide treatment. Yet it must be used with care, because technical limits, false results, cost, and access gaps can all affect its value.
Lung cancer care is becoming more molecular, more personalised, and more responsive to change over time. ctDNA sits at the centre of that shift. Its greatest promise is not simply finding cancer DNA in a blood sample. It is helping clinicians make better-timed, better-matched decisions for the person behind the test.
AI generated marketing material
Comments